ALS Association awards more than $1.9 million in research grants
The TREAT ALS grant portfolio is comprised of the TREAT ALS Drug Development Contract grant and ALS Association-Initiated grants -- worth more than $1.9 million.
Grants were awarded to David Rodman, miRagen Therapeutics, Boulder, Colorado; Howard Weiner, Ann Romney Center for Neurologic Diseases; Raymond Roos, University of Chicago; J. Paul Taylor, St. Jude Children’s Research Hospital; Jinghui Zhang, St. Jude Children’s Research Hospital; Michael Benatar, University of Miami; John Landers, UMass Medical School, Worcester, Massachusetts; Cathleen Lutz, The Jackson Laboratory, Maine; and Eliahu Heldman of Lauren Sciences LLC, New York.
For full descriptions of the projects, log on to www.alsa.org.
Affecting millions of people worldwide, ALS is a disease of the nerve cells in the brain and spinal cord that leads to loss of muscle control, total paralysis and death, typically within two to five years after diagnosis.
As of now, there is no cure for ALS. Only one drug that minimally increases the survival rate of ALS patients exists on the market.
Organizations in this story
ALS Association 1275 K Street Northwest Washington, DC - 20005